Full text
4/2026
vol. 113
Original article
Somatic mosaicism in pediatric dermatology: molecular diagnostics, literature review and recommendations from a reference center
Clinical Department of Pediatric Dermatology and Vascular Anomalies, Faculty of Medical Sciences in Katowice, Medical University of Silesia,, Katowice, Poland
MedGen Medical Centre, Warsaw, Poland
Dermatol Rev/Przegl Dermatol 2026, 113, 189–197
Data publikacji online: 2026/11/16
- Groesser L., Herschberger E., Ruetten A., Ruivenkamp C., Lopriore E., Zutt M., et al.: Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet 2012, 44, 783-787.
- Lim Y., Moscato Z., Choate K.A.: Mosaicism in cutaneous disorders. Annu Rev Genet 2017, 51, 123-141.
- Ayturk U.M., Couto J.A., Hann S., Mulliken J.B., Williams K.L., Huang A.Y., et al.: Somatic activating mutations in GNAQ and GNA11 are associated with congenital hemangioma. Am J Hum Genet 2016, 98, 789-795.
- Kuentz P., St-Onge J., Duffourd Y., Courcet J.B., Carmignac V., Jouan T., et al.: Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing. Genet Med 2017, 19, 989-997.
- Kim J.H., Hwang S., Son H., Kim D., Kim I.B., Kim M.H., et al.: Analysis of low-level somatic mosaicism reveals stage- and tissue-specific mutational features in human development. PLoS Genet 2022, 18, e1010404.
- Mirzaa G., Timms A.E., Conti V., Boyle E.A., Girisha K.M., Martin B., et al.: PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution. JCI Insight 2016, 1, e87623.
- Keppler-Noreuil K.M., Rios J.J., Parker V.E.R., Semple R.K., Lindhurst M.J., Sapp J.C., et al.: PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A 2015, 167A, 287-295.
- Shirley M.D., Tang H., Gallione C.J., Baugher J.D., Frelin L.P., Cohen B., et al.: Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med 2013, 368, 1971-1979.
- Keppler-Noreuil K.M., Parker V.E.R., Darling T.N., Martinez-Agosto J.A.: Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies. Am J Med Genet C Semin Med Genet 2016, 172C, 402-421.
- Happle R.: The categories of cutaneous mosaicism: a proposed classification. Am J Med Genet A 2016, 170A, 452-459.
- Grzeschik K.H., Bornholdt D., Oeffner F., König A., del Carmen Boente M., Enders H., et al.: Deficiency of PORCN, a regulator of Wnt signaling, is associated with focal dermal hypoplasia. Nat Genet 2007, 39, 833-835.
- Wang X., Sutton V.R., Peraza-Llanes J.O., Yu Z., Rosetta R., Kou Y.C., et al.: Mutations in X-linked PORCN, a putative regulator of Wnt signaling, cause focal dermal hypoplasia. Nat Genet 2007, 39, 836-838.
- Tollefson M.M., McEvoy M.T.: Goltz syndrome in a moderately affected newborn boy. Int J Dermatol 2009, 48, 1116-1118.
- Maas S.M., Lombardi M.P., van Essen A.J., Wakeling E.L., Castle B., Temple I.K., et al.: Phenotype and genotype in 17 patients with Goltz-Gorlin syndrome. J Med Genet 2009, 46, 716-720.
- Stevenson D.A., Chirpich M., Contreras Y., Hanson H., Dent K.: Goltz syndrome and PORCN mosaicism. Int J Dermatol 2014, 53, 1481-1484.
- Carmignac V., Mignot C., Blanchard E., Kuentz P., Aubriot-Lorton M.H., Parker V.E.R., et al.: Clinical spectrum of MTOR-related hypomelanosis of Ito with neurodevelopmental abnormalities. Genet Med 2021, 23, 1484-1491.
- Salas-Labadía C., Gómez-Carmona S., Cruz-Alcívar R., Martínez-Anaya D., Del Castillo-Ruiz V., Durán-McKinster C., et al.: Genetic and clinical characterization of 73 pigmentary mosaicism patients: revealing the genetic basis of clinical manifestations. Orphanet J Rare Dis 2019, 14, 259.
- Akgumus G., Chang F., Li M.M.: Overgrowth syndromes caused by somatic variants in the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway. J Mol Diagn 2017, 19, 487-497.
- Luks V.L., Kamitaki N., Vivero M.P., Uller W., Rab R., Bovee J.V.M., et al.: Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr 2015, 166, 1048-1054.e1-e5.
- Alomari A.I.: Characterization of a distinct syndrome that associates complex truncal overgrowth, vascular, and acral anomalies: a descriptive study of 18 cases of CLOVES syndrome. Clin Dysmorphol 2009, 18, 1-7.
- Canaud G., Lopez Gutierrez J.C., Irvine A.D., Vabres P., Hansford J.R., Ankrah N., et al.: Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS). Genet Med 2023, 25, 100969.
- McNulty S.N., Evenson M.J., Corliss M.M., Love-Gregory L.D., Schroeder M.C., Cao Y., et al.: Diagnostic utility of next-generation sequencing for disorders of somatic mosaicism: a five-year cumulative cohort. Am J Hum Genet 2019, 105, 734-746.
- Conlin L.K., Thiel B.D., Bonnemann C.G., Medne L., Ernst L.M., Zackai E.H., et al.: Mechanisms of mosaicism, chimerism and uniparental disomy identified by single nucleotide polymorphism array analysis. Hum Mol Genet 2010, 19, 1263-1275.
- Grochowski C.M., Gibbs R.A., Doddapaneni H.: Validation of single-nucleotide mosaic variants through droplet digital PCR. Curr Protoc 2024, 4, e1041.
Copyright: © 2026 Polish Dermatological Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

